Drugs / PF-06671008
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02659631 | Apr 2016 → Mar 2019 | neoplasm | Pfizer | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06671008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02659631 ↗ |
| Route | Intravenous | “received PF-06671008 (1.5-400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle.” PMID 35493516 ↗ Apr 2022 |